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GENERAL

ENDOCRINOLOGY

A Humanized Pattern of Aromatase Expression Is
Associated with Mammary Hyperplasia in Mice

Division of Reproductive Biology Research, Departments of Obstetrics and Gynecology (H.Z., E.K.P.,
D.C.B., J.S.C., D.C., M.D., R.T.C., S.E.B.), Medicine (M.Z.), Pathology (C.V.C.), and Physiology (R.T.C.),
Feinberg School of Medicine, Northwestern University, Chicago, Illinois 60611; Laboratory of Proteomics
and Analytical Technologies (X.X.,T.D.V.), Science Applications International Corporation-Frederick,
National Cancer Institute, National Institutes of Health, Frederick, Maryland 21702; and Department of
Molecular and Cellular Biology (F.J.D.), Baylor College of Medicine, Houston, Texas 77030

Aromatase is essential for estrogen production and is the target of aromatase inhibitors, the most
effective endocrine treatment for postmenopausal breast cancer. Peripheral tissues in women,
including the breast, express aromatase via alternative promoters. Female mice lack the promoters
that drive aromatase expression in peripheral tissues; thus, we generated a transgenic humanized
aromatase (Aromhum) mouse line containing a single copy of the human aromatase gene to study
the link between aromatase expression in mammary adipose tissue and breast pathology. Aromhum
mice expressed human aromatase, driven by the proximal human promoters II and I.3 and the distal
promoter I.4, in breast adipose fibroblasts and myoepithelial cells. Estrogen levels in the breast
tissue of Aromhum mice were higher than in wild-type mice, whereas circulating levels were similar.
Aromhum mice exhibited accelerated mammary duct elongation at puberty and an increased incidence of lobuloalveolar breast hyperplasia associated with increased signal transducer and activator of transcription-5 phosphorylation at 24 and 64 wk. Hyperplastic epithelial cells showed remarkably increased proliferative activity. Thus, we demonstrated that the human aromatase gene can
be expressed via its native promoters in a wide variety of mouse tissues and in a distribution pattern
nearly identical to that of humans. Locally increased tissue levels, but not circulating levels, of estrogen
appeared to exert hyperplastic effects on the mammary gland. This novel mouse model will be valuable
for developing tissue-specific aromatase inhibition strategies. (Endocrinology 153: 2701–2713, 2012)

A

romatase, encoded by a single gene, is essential for
estrogen production. Estrogens exert their effects by
binding to two distinct receptors, estrogen receptor (ER)-␣
and ER␤ (1, 2). Aromatase and epithelial ER␣ expression
are required for normal mammary gland development involving ductal elongation and outgrowth during puberty
(3, 4). Aromatase and estrogen are also involved in the
development of hormone-dependent breast cancer, and
aromatase inhibitors are the most effective endocrine

treatment for postmenopausal breast cancer (5, 6). The
causal relationship between estrogen and breast cancer
has been well documented in studies of several breast
cancer cell lines (7). Ligand-activated ER acts in the
nucleus as a transcriptional factor or interacts with and
activates cytoplasmic signaling molecules including cSrc, signal transducer and activator of transcription
(Stat), ERK, and phosphatidylinositol 3-kinase (PI3K)/
Akt (8, 9).
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in the clinical setting, and they remain mostly
unrecognized.
We and others have proposed that adipose tissue aromatase is the major determinant of local levels of estrogen
in the breast and is linked to breast cancer risk (19, 20).
Because female mice lack the promoters for aromatase
expression in extragonadal tissues, such as the breast adipose, we generated a transgenic humanized aromatase
(Aromhum) mouse line that contains a single copy of the
human aromatase gene and mimics human physiology
with respect to tissue-specific patterns of aromatase expression and estrogen production. Here we report the molecular and functional aspects of humanized aromatase
expression in the mammary gland and other peripheral
tissues in the Aromhum mice and the potential application
for the study of the relationship between breast aromatase
expression, estrogen production, obesity, and breast cancer pathology.

Materials and Methods
Bacterial artificial chromosome (BAC) clones
characterization and generation of transgenic mice
Three BAC clones were obtained from the BACPAC Resources Center of Children’s Hospital Oakland Research Institute (Oakland, CA). BAC DNA was transformed into competent
bacteria (DH10B) and grown in Luria-Bertani medium containing 12.5 g/ml chloramphenicol. BAC DNA was extracted by
the alkaline lysis method. The sizes of the BAC were estimated by
NotI linearized restriction digestion and 0.6% agarose gel electrophoresis. The ends of the BAC were sequenced, and a largescale EcoRV restriction map was generated (data not shown).
Aromatase gene integrity was confirmed with PCR primer pairs
that hybridize to its promoter regions (I.1, I.4, I.7, I.f, I.6, I.3, and
PII) and coding region (exon II and exon X; data not shown) (21,
22). One of the BAC clones (RP11–1134K1) contained the complete aromatase locus and was subsequently used for all studies.
Linearized RP11-1134K1 DNA was microinjected into the pronucleus of strain FVB/N-fertilized oocytes at the Baylor College
of Medicine Genetically Engineered Mouse Core (Houston, TX).
Integration of the transgene in the offspring was assessed by PCR
analysis. The primer sequences used for screening PCR are listed
in Supplemental Table 1, published on The Endocrine Society’s
Journals Online web site at http://endo.endojournals.org.

Genotyping and animals
Genotypic analyses were performed by PCR using genomic
DNA isolated from the tails of potential founder mice. Initial
genotyping was done using the PCR primers described above.
Similar phenotypes of mammary hyperplasia were observed in
two independent transgenic lines, F1771 and F1772. Both lines
contained the complete human aromatase coding region. The
F1771 line contained a longer promoter region, starting 75 kb
upstream of the ATG translation start site and including promoters I.4, I.7, I.f, I.6, I.3, and PII. The F1772 line contained a
shorter promoter region, starting 4.3 kb upstream of the trans-
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Both human and mouse aromatase genes comprise 10
exons, nine of which are coding exons (II-X) that span
approximately 30 kb. A number of alternative noncoding
first exons are expressed in a tissue-specific manner and
are spliced onto a common junction upstream of the translation start site, resulting in the synthesis of identical aromatase proteins regardless of the first exon used (5, 10). In
humans, 10 alternative tissue-specific first exons have
been identified in various tissues: exons I.1, I.2, and I.2a in
placenta (⫺93, ⫺78, and ⫺13 kb); I.4 in adipose tissue
and skin (⫺73 kb); I.5 in fetal tissues (⫺43 kb); I.7 in
endothelial cells (⫺36 kb); I.f in brain (⫺33 kb); I.6 in
bone (⫺1kb); I.3 in breast fat proximal to cancer (⫺0.3
kb); and PII in gonads (⫺0.1 kb) (11). In contrast to the
human gene, there are only two tissue-specific untranslated first exons in the female mouse aromatase gene: a
gonadal-specific exon (⫺0.1 kb) and a brain-specific exon
(⫺35.5 kb) (12–14). Compared with mice, then, women
express aromatase via alternatively used promoters in a
number of additional peripheral tissues (e.g. breast adipose), giving rise to drastically distinct tissue distribution
patterns of aromatase expression.
Thus far, two transgenic mouse lines expressing human
aromatase have been reported: mice expressing human
aromatase driven by the mouse mammary tumor viruslong-terminal repeat promoter (int-5/aromatase) and mice
expressing human aromatase driven by the human ubiquitin C promoter (15). Int-5/aromatase female mice exhibit mammary duct hyperplasia, ductal dysplastic lesions, alveolar hyperproliferation, and fibroadenomas
(16). The phenotype of the mice expressing human aromatase driven by the human ubiquitin C promoter is characterized by mammary hyperplasia in 15-month-old females (15, 17). Although these two animal models have
helped in understanding the molecular mechanisms involved in the formation of the mammary glands and the
development of breast cancer, they do not mimic human
aromatase expression patterns in peripheral tissues driven
by native promoters; therefore, they are not ideal models
for developing tissue-specific aromatase inhibition strategies (12, 18).
In premenopausal women, the ovaries express high levels of aromatase and are the main source of estrogens.
However, extragonadal aromatase expression plays a key
role in estrogen production, especially in men and postmenopausal women, because ovarian aromatase expression ceases after menopause (11). Estrogens synthesized
locally in extragonadal sites do not typically enter the circulation; rather, local estrogens exert intracrine, autocrine, paracrine, and juxtacrine effects, acting directly on
cells and tissues. These effects are very difficult to measure
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lation start site and including promoters I.6, I.3, and PII. Mice
were maintained on a 14-h light, 10-h dark cycle, with standard
chow (7912; Harlan Teklad, Madison, WI) and water available
ad libitum. Animals were housed according to the National Institutes of Health Guide for the Care and Use of Laboratory
Animals. All procedures were approved by the Animal Care and
Use Committees of Baylor College of Medicine and Northwestern University. All tissues and serum were collected from mice
between 1000 and 1200 h to remove variability in daily hormone
fluctuations.

Total RNA from various mouse tissues was extracted at 24
and 64 wk of age using TRIzol reagent according to the manufacturer’s instructions (Sigma, St. Louis, MO). cDNA was reverse transcribed using oligo(deoxythymidine) primers and a reverse transcriptase kit (Invitrogen Corp., Carlsbad, CA). Realtime PCR was performed with the Taqman and Power SYBR®
green PCR master mix kit according to the manufacturer’s instructions (Applied Biosystems, Foster City, CA) in an ABI
7900HT fast real-time PCR system (Applied Biosystems). The
primer sequences used for real-time PCR are listed in Supplemental Table 1. Real-time PCR cycler conditions were: 50 C for
2 min, 95 C for 10 min, and 40 cycles of 95 C for 15 sec and 60
C for 1 min. PCR results were normalized to mouse glyceraldehyde-3-phosphate dehydrogenase (GAPDH) gene expression
(23). Cycle threshold values at or above 40 cycles were considered to be below the level of detection.

5ⴕ-Rapid amplification of cDNA ends (RACE)
To determine the transcriptional start sites of human aromatase transcripts from various tissues, 5⬘-RACE was performed
using the SMART RACE cDNA amplification kit (CLONTECH, Mountain, CA) as described previously (12). The primary touchdown PCR reverse primers used were as follows:
mouse touchdown reverse primer (5⬘-GACTCTCATGAATTCTCCATA CATCT-3⬘) and human touchdown reverse
primer (5⬘-GTCCAATTCCCATGCAGTAGCCAGGA-3⬘). If
the primary PCR reaction failed to give the distinct bands of
interest, a secondary, or nested⬙ PCR was performed with the
mouse nested reverse primer (5⬘-AATGAGGGGCCCAATTCCCAGA-3⬘) and human nested reverse primer (5⬘-CCAAGAGAAAAAGGCCAGTGAGGAGCA-3⬘). RACE products
were cloned into the pCR-TOPO TA cloning vector and subsequently sequenced.

Exon-specific RT-PCR amplification
Total RNA was extracted from 24-wk-old left inguinal mammary gland (gland no. 4), and cDNA was synthesized using oligo(deoxythymidine) primers with a reverse transcriptase kit (Invitrogen, Camarillo, CA). To amplify the human transcript
variants in the mammary gland (driven by promoters PII, I.3, and
I.4), we used forward primers designed to hybridize to the different 5⬘-untranslated regions of each transcript and a reverse
primer that hybridized to coding exon III (24). The PCR was run
as follows: 4 min at 95 C, followed by 35 cycles of 30 sec at 94
C, 30 sec at 60 C, and 1 min at 72 C, and a final extension of 9
min at 72 C.

2703

Whole mounts, tissue histology, and
immunohistochemistry
The morphology of the mammary glands was examined using
the whole-mount technique (25). Glands were spread on glass
slides, fixed, and subjected to carmine (Sigma Chemicals) staining. To prepare mammary gland sections, inguinal glands were
removed from mice, fixed in 4% phosphate-buffered paraformaldehyde overnight, and then transferred to 70% ethanol. Tissues were embedded in paraffin and sectioned at 5 m. After
deparaffinization, rehydration, and antigen retrieval by heating
in antigen unmasking solution (Vector Laboratories, Burlingame, CA), primary antibodies [human aromatase (1:100, MCA
2077); AbD Serotec, Oxford, UK; or Ki67 antibody (1:200,
ab66155); Abcam, Cambridge, MA] were applied to the sections. After incubation at 37 C for 1 h or 4 C overnight, the
sections were washed with PBS and incubated with a biotinylated
horse-antimouse secondary antibody (1:600, BA-2000;Vector
Laboratories) at 37 C for 30 min followed by avidin-biotinhorseradish peroxidase complex (Vector, Laboratories). Sections were examined using a Zeiss Axio Scope microscope (Zeiss,
Gottingen, Germany) (26).

Protein extraction and immunoblotting
Mammary gland total protein was extracted in a buffer containing 10 mmol/liter Tris (pH 7.4), 150 mmol/liter NaCl, 1
mmol/liter EDTA, 1 mmol/liter EGTA, 0.5% Nonidet P-40, protease inhibitors (2 mmol/liter phenylmethylsulfonyl fluoride, 10
mg/ml leupeptin, and 10 mg/ml aprotinin), and phosphatase inhibitors (100 mmol/liter sodium fluoride, 10 mmol/liter sodium
pyrophosphate, and 2 mmol/liter sodium orthovanadate). Lysates were centrifuged at 50,000 ⫻ g for 60 min at 4 C. Protein
concentrations were determined using the bicinchoninic acid
protein assay (Pierce, Rockford, IL) according to the manufacturer’s instructions. Samples containing 25 g of protein were
boiled for 4 min in a reducing Laemmli sample buffer containing
80 mmol/liter dithiothreitol and subjected to electrophoresis on
10% sodium dodecyl sulfate-polyacrylamide gels. Proteins were
then transferred from gels to nitrocellulose membrane. The
membranes were blocked with 5% insulin-free BSA in TBSTween 20, and proteins were detected using various antibodies
[phospho-Stat5 (1:500, 71-6900) and Stat5a (1:1000, 13-3600)
antibodies (Invitrogen); ␤-casein (H-7) antibody (1:500, sc166520) (Santa Cruz Biotechnology, Santa Cruz, CA); and ␤-actin antibody (1:6000, A1978) (Sigma Chemicals)]. After extensive washings, the immune complexes were detected with
horseradish peroxidase conjugated with specific secondary antiserum [(1:5000, antirabbit IgG (7074), antimouse IgG (7076);
Cell Signaling Technology, Inc., Danvers, MA)] followed by an
enhanced chemiluminescence reaction. The blots were analyzed
by densitometry and quantified with MultiGauge software (Fuji
PhotoFilm, Valhalla, NY).

Serum and tissue hormone levels
Blood samples were obtained from the retroorbital vein or tail
vein. Serum estradiol (E2) was measured by ELISA (ES 180S;
Calbiotech Inc., Spring Valley, CA), serum testosterone, progesterone, and FSH levels were measured by RIA, and LH was measured by immunoradiometric assay by the University of Virginia
Center for Research in Reproduction Ligand Assay and Analysis
Core (Charlottesville, VA) (27–30). The mouse LH and FSH
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Superovulation
Pregnant mares’ serum gonadotropin (PMSG) and human
chorionic gonadotropin (HCG) was obtained from Sigma Chemicals. Ten 8-wk-old mice for each genotype [wild type (WT),
F1772, F1771] were injected ip with 5 IU PMSG. Forty-eight
hours after the PMSG injection, five of each genotype were killed
and ovaries were collected. The other five were injected ip with
5 IU HCG. Sixteen hours after the HCG injection, the second five
mice were killed and ovaries were collected for the further investigation. Five 8-wk-old mice for each genotype were injected
with vehicle alone as controls.

Vaginal opening and estrous cyclicity
Beginning 10 d after birth, females were examined daily for
the onset of vaginal opening. To examine various stage of the
estrous cycle, vaginal lavages with 0.9% NaCl from female mice
(6.5– 8 wk old) were obtained and viewed under a microscope
daily between 0900 and 1000 h for at least two cycles (8 –9
consecutive days). A normal estrous cycle was defined as 2 d of
leukocytic cytology followed by 1 d of nucleated and 1–2 d of
cornified cytology.

Statistical analysis
Results are expressed as mean ⫾ SE. Statistically significant
differences at P ⬍ 0.05 were determined using a one-factor
ANOVA followed by a t test.

Results
Generation of the transgenic Aromhum mouse
To develop an animal model in which the human aromatase gene is regulated via its tissue-specific alternative
promoters in various tissues, we first screened and obtained a human BAC clone containing the human aromatase coding sequence flanked by its full-length, 93-kb 5⬘regulatory region and the 3⬘-polyadenylation site. We
injected a single copy of the BAC clone into pronuclear
mouse embryos to generate the Aromhum transgenic
mouse line. PCR primers designed to amplify the human
aromatase coding region and the major promoter sequences were used to identify six initial founders containing the transgene. A schematic of the human BAC clone

construct used to generate the Aromhum line and a representative PCR of genomic DNA from two of the six founders (F1772 and F1771) are shown in Fig. 1A. Both F1772
and F1771 harbored the full (30 kb) coding region and its
3⬘ end. F1772 had a 4.3-kb 5⬘-flanking region containing
only the proximal promoters I.6 and I.3/II, whereas F1771
included a greater than 78-kb 5⬘-flanking region encompassing the more distal promoters I.4, I.7, and I.f as well
as promoters I.6 and I.3/PII (Fig. 1A). As in humans, the
encoded aromatase protein was identical in both founders, regardless of the promoters present in the transgene.
To determine the aromatase mRNA expression profile
in female Aromhum mouse tissues, 24-wk-old mice were
euthanized and multiple tissues were collected and analyzed using real-time RT-PCR (Table 1). Consistent with
patterns of extragonadal aromatase expression in women,
human aromatase mRNA was detected in the ovary, hypothalamus, pituitary, uterus, mammary gland, aorta,
lung, stomach, adrenal gland, bladder, gonadal fat, sc fat,
and abdominal muscle in both F1771 and F1772 Aromhum
mouse lines and in the quadriceps muscle, brown adipose
tissue, heart, liver, spleen, intestine, kidney, and bone in
the F1771 line (Table 1). We used 5⬘-RACE to detect promoter-specific mRNA species. The term present denotes
only the amplification of the coding region of human aromatase mRNA species by real-time PCR; we were, however, unable to detect promoter-specific 5⬘-untranslated
regions in these tissues using 5⬘-RACE. If 5⬘-RACE produced a promoter-specific mRNA, this promoter was indicated in Table 1. Mouse aromatase mRNA in the ovary
and brain was similar between WT and Aromhum mice
(Supplemental Fig. 1). In the ovary aromatase is mainly
expressed in granulosa cells. Aromhum mice showed strong
expression of human aromatase mRNA in the ovary. We
used PMSG in conjunction with HCG to superovulate
female mice. Both mouse and human aromatase mRNA
levels were significantly increased in WT, F1772, and
F1771 mice after administration of PMSG for 48 h and
significantly decreased in all mice after HCG injection for
16 h compared with PSMG treatment (Fig. 1, B and C).
These data demonstrated that both the aromatase transgene and endogenous aromatase have a similar expression
pattern. The endogenous mouse aromatase was lower in
PMSG-treated F1772 mice as compared with PMSGtreated WT and F1771 mice but was higher compared
with vehicle-treated F1772 mice (Fig. 1, B and C). Thus,
the human transgene did not change the general pattern of
endogenous aromatase expression. To determine the fertility/reproductive function of Aromhum mice, transgenic
and WT females were mated with WT males. The average
litter size between WT and Aromhum mice was similar
(Fig. 1D). Ovarian appearance, including the number of
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assays are in the Methods section of the web site of this facility
(http://www.medicine.virginia.edu/research/institutes-and-programs/crr/lab-facilities/assay-methods-page). Estrogens [estrone
(E1) and E2] and estrogen metabolites [2-methoxyestrone
(2ME1), 2-methoxyestradiol (2ME2) and estriol (E3)] in serum
and the mammary gland were determined by liquid chromatography-tandem mass spectrometry (LC-MS2) at the National Cancer
Institute/National Institutes of Health, as described previously (31).
Serum prolactin levels were measured by bioassay (32). The determination of the stage of the estrous cycle was made by vaginal
smears. To measure serum E2 levels by ELISA at various stages of
the estrous cycle (Calbiotech), serum from 6.5-wk-old mice was
collected for 8 –9 consecutive days from the tail vein.
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corpus lutea (ovulation), was similar between WT and
Aromhum mice (data not shown).
Expression of human aromatase in mammary
adipose fibroblasts and myoepithelia of Aromhum
mice via its cognate promoters PII, I.3, and I.4
We next analyzed each of the transgenic lines for the
expression and promoter usage of aromatase in mammary
gland. Total RNA was isolated from biopsies of inguinal
mammary glands (no. 4) from 24-wk-old Aromhum and
WT littermates. In Aromhum mice, we found human aromatase expression in mammary gland and that the level of
human aromatase mRNA was significantly higher in
F1771 mice than that in F1772 mice (Fig. 1E). Human
aromatase mRNA was not detected in the WT mammary

glands. We then used exon-specific RT-PCR to determine
promoter usage in the mammary gland of Aromhum mice
and found that human aromatase expression was driven
by PII, I.3, and I.4 in F1771 mice and by I.3 in F1772 mice
(Fig. 1F). We used immunohistochemistry to localize human aromatase within the mammary gland of Aromhum
mice; as expected, human aromatase immunostaining was
absent in WT mice. In 24-wk-old Aromhum mice, staining
was observed in adipose fibroblast cells and myoepithelial
cells but absent in epithelial cells (Fig. 1G).
Increased local estrogen concentration in the
breast tissue of Aromhum mice
To determine whether elevated human aromatase expression in the Aromhum mouse mammary tissue is ac-
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FIG. 1. Generation and characterization of the Aromhum transgenic mouse line. A, Schematic of the human BAC clone construct used to generate
Aromhum transgenic mice. RT-PCR showed transmission of the transgene to the germline. F1772 contained exons PII, I.3, and I.6. F1771 contained
all first exons of the aromatase gene except I.1. Mouse (B) and human (C) aromatase mRNA levels in ovaries of superovulated mice are shown.
Females were given one of the following: 1) PMSG for 48 h, 2) PMSG for 48 h followed by HCG for 16 h, or 3) vehicle (Veh) alone. Ovaries were
collected after treatment for the further analysis as described in Materials and Methods (n ⫽ 5 mice per group). #, P ⬍ 0.05 vs. vehicle; *, P ⬍
0.05 vs. PMSG. D, Average litter size of Aromhum or WT females mated to WT males (n ⫽ 8 mice per group). E, Human aromatase mRNA was
expressed in the mammary glands of Aromhum mice. *, P ⬍ 0.05. F, Exon-specific RT-PCR confirmed the different promoter driven human
aromatase expression in the mammary gland of Aromhum mice. GAPDH mRNA levels served as the control. Data are representative of three
independent experiments. G, Immunohistochemical localization of human aromatase in the mammary glands of Aromhum mice (n ⫽ 4 –5 mice per
group). Arrows indicate aromatase positive staining. Bar, 50 m.
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mRNA expression profile of human aromatase in various tissues of 24-wk-old female Aromhum mice
WT

F1772

F1771

H Arom

M Arom

H Arom

M Arom

H Arom

M Arom

Ovary
Hypothalamus
Pituitary
Nonpregnant uterus
Mammary gland
Aorta
Lung
Stomach
Adrenal gland
Bladder
Gonadal fat
Subcutaneous fat
Abdominal muscle
Quadriceps muscle
Brown adipose
Heart
Liver
Spleen
Intestine
Kidney
Bone

⫺
⫺
⫺
⫺
⫺
⫺
⫺
⫺
⫺
⫺
⫺
⫺
⫺
⫺
⫺
⫺
⫺
⫺
⫺
⫺
⫺

Pgon
Pbr
⫺
⫺
⫺
⫺
⫺
⫺
⫺
⫺
⫺
⫺
⫺
⫺
⫺
⫺
⫺
⫺
⫺
⫺
⫺

PII
Present
Present
Present
PII/I.3
Present
Present
Present
Present
Present
Present
Present
Present
⫺
⫺
⫺
⫺
⫺
⫺
⫺
⫺

Pgon
Pbr
⫺
⫺
⫺
⫺
⫺
⫺
⫺
⫺
⫺
⫺
⫺
⫺
⫺
⫺
⫺
⫺
⫺
⫺
⫺

PII
I.f
PresentPresentPII/I.3/I.4
I.4
I.4
PresentPresentI.4
PresentPresentI.4
I.4
PresentPresentPresentPresentI.7/I.f
PresentI.4

Pgon
Pbr
⫺
⫺
⫺
⫺
⫺
⫺
⫺
⫺
⫺
⫺
⫺
⫺
⫺
⫺
⫺
⫺
⫺
⫺
⫺

Quantitative real-time RT-PCR was used to determine the presence or absence (⫺) of mouse and human aromatase mRNA in various tissues of WT
mice and lines F1772 and F1771. 5⬘-RACE identified mRNA transcribed from each promoter (PII, I.f, I.4, I.3) in the human aromatase transgene or
native mouse promoters. Pgon, Mouse gonadal aromatase promoter; Pbr, mouse brain aromatase promoter; H Arom, human aromatase; M Arom,
mouse aromatase.

tions were lower in F1771 by 57 and 37%, respectively,
compared with WT and F1772 females (Fig. 2B). The decreased LH in the F1771 line also accounted for the significantly lower serum testosterone levels (Fig. 2D) and a
nonsignificant trend of lower progesterone levels in F1771
females (Fig. 2E) because LH regulates ovarian progesterone secretion. Serum concentrations of FSH and prolactin
remained unchanged between WT,
F1772, and F1771 littermates (Fig. 2, C
and F).
Because serum concentrations measured by ELISA of the biologically active estrogen, E2, were not different between WT, F1772, and F1771 mice, we
applied a much more sensitive technology, LS-MS2, to measure the total serum concentrations of the estrogens (E1
and E2) and its metabolites (E3, 2ME1,
and 2ME2). Serum E1 levels were
slightly but significantly increased in
F1772 and F1771 mice compared with
WT mice (Fig. 3A). Serum E2 and E3
levels were also modestly but significantly higher in F1772 mice compared
FIG. 2. Serum testosterone and LH levels are lower in Aromhum mice compared with WT
with WT mice (Fig. 3A). However, the
littermates. Mouse sera were collected from 24-wk-old mice. Serum E2 (A), LH (B), FSH (C),
total levels of estrogens were similar betestosterone (D), progesterone (E), and prolactin (F) were measured by ELISA, RIA, or bioassay
tween WT, F1772, and F1771 females,
(n ⫽ 11–12 mice per group). *, P ⬍ 0.05 vs. WT mice.

companied by increased tissue estrogen levels and change
in circulating hormone levels, we compared mammary tissue E2 levels and peripheral serum levels of estrogens, progesterone, testosterone, prolactin, and the gonadotropins
LH and FSH using ELISA and RIA technologies (Fig. 2).
Serum E2 levels were similar between WT, F1772, and
F1771 females (Fig. 2A), as were those in the mammary
tissue (data not shown). However, serum LH concentra-
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to puberty), mammary tissues from
both WT and Aromhum showed similar
morphological changes, with prominent duct elongation and a few alveoli
growing from terminal branches at the
end buds; however, ductal outgrowth
was accelerated in F1771 mice compared with WT mice. We measured the
ductal length from the mammary
lymph node to the tip of the terminal
end buds in 7-wk-old mice and found
that mammary ducts of F1771 mice
were significantly longer than those of
WT mice (Fig. 4, A and B). Mammary
gland morphology and ductal elongation were similar in WT and Aromhum
mouse lines at 12 wk of age (postpuFIG. 3. Mammary unconjugated estrogens are higher in Aromhum mice compared with WT
bertal, Fig. 4C). The vaginal opening,
littermates. Serum (A) and mammary gland (B) unconjugated estrogens and estrogen
2
an external marker for the onset of pumetabolites were measured by LC-MS assay. E1, E2, E3, 2ME1, and 2ME2 are shown. mRNA
levels of ER␣ (C) and PR (D) were measured by real-time RT-PCR (n ⫽ 15 mice per group).
berty, was first observed at similar ages
*, P ⬍ 0.05 vs. WT mice.
in WT, F1772, and F1771 mice (29.8 ⫾
0.4, 30 ⫾ 0.8, and 29.2 ⫾ 0.4 d, respectively; n ⫽ 6, Fig. 4D). These data sugwhich concurred with E2 levels measured by ELISA (Fig.
2A). Serum 2ME1 levels were significantly decreased and gest that the observed increase in ductal length in the
2ME2 levels were significantly increased in F1772 and F1771 lines cannot be explained by early puberty. Serum
E2 levels at the proestrous stage of WT and Aromhum mice
F1771 mice compared with WT mice.
To determine the functionality of human aromatase were significantly higher than the serum E2 levels at ditransgene and production of estrogens in the mammary estrous or estrous stages. However, the serum E2 levels
gland, we also measured the local levels of mammary es- were not different between WT, F1772, and F1771 mice
trogens and their metabolites using LS-MS2 (Fig. 3B). To- within the same estrous stage (Fig. 4E). This result sugtal mammary estrogen levels were significantly higher in gested that the accelerated ductal growth at puberty is not
F1772 by 1.8-fold and in F1771 by 2.5-fold, compared secondary to increased serum estrogen levels but more
with WT mice (Fig. 3B). Compared with WT mice, E1 likely due to excess local estrogen production in the mamlevels were 3.1-fold higher in F1772 and 3.8-fold higher in mary gland.
F1771 mice; E2 levels were 1.4-fold higher in F1772 and
2.4-fold higher in F1771 mice; and 2ME2 levels were sig- Mammary aromatase expression and estrogen
nificantly higher in F1772 and F1771 mice (P ⬍ 0.05). No production are associated with mammary
hum
mice
differences in mammary E3 or 2ME1 levels were observed hyperplasia in Arom
We showed that the Aromhum mice express human arobetween WT, F1772, and F1771 mice (Fig. 3B). ER␣ and
progesterone receptor (PR) mRNA levels did not differ matase in several peripheral tissues, including breast fat,
under the control of alternative promoters and produce
between WT, F1772, and F1771 mice (Fig. 3, C and D).
estrogen in the mammary glands, mimicking human patterns of extraovarian estrogen production. To determine
Increased ductal elongation and outgrowth during
the effects of local estrogen on breast tissue in the Aromhum
puberty in Aromhum mice
E2 has been shown to act directly on the mammary mouse, we analyzed mouse mammary morphology and
gland to stimulate ductal elongation during puberty (33). histology at 24 and 64 wk of age. Figure 5A shows wholeTo determine whether expression of human aromatase in mount staining of mammary glands at 24 wk of age. Virgin
the mammary gland affects ductal morphogenesis, we ob- WT females exhibited normal mammary ductal morphoserved mammary morphological changes in mice at 5, 7, genesis as reflected by the presence of an ordered ductal
or 12 wk of age. At 5 wk of age (prepubertal), the size and network with normal side branching. In contrast, virgin
morphology of the mammary glands from WT and Arom- Aromhum mice displayed disseminated mammary gland
hum
mice were similar (Fig. 4C). At 7 wk of age (equivalent hyperplasia indicated by excessive ductal side branching
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Mammary hyperplasia is induced
by epithelial hyperproliferation in
Aromhum mice
We observed a significantly higher
epithelial cell content in the mammary
FIG. 4. Increased mammary ductal elongation during puberty in F1771 Aromhum mice
glands of Aromhum mice compared
compared with WT mice. A, Whole-mount staining was performed on mammary glands from
with WT mice, which may be due to an
WT, F1772, and F1771 mice at 7 wk of age. Glands were spread on glass slides, fixed, and
increase in estrogen-stimulated epithesubjected to carmine staining. Bar, 1000 m. B, The length of mammary ducts from 7-wk-old
(B) and 5- and 12-wk-old females (C) were measured from the lymph node to the tip of the
lial proliferation. We performed Ki67
terminal end buds. D, The time of vaginal opening in Aromhum mice was not different from
immunohistochemical analysis to comlittermate controls (n ⫽ 6 mice per group). E, Serum E2 levels were measured based on cycle
pare the level of epithelial cell proliferstage. The 6.5-wk-old mice were bled for 8 –9 consecutive days. Cycle stage was determined
by vaginal cytology (n ⫽ 10 –11 mice per group). *, P ⬍ 0.01 vs. diestrous stage; #, P ⬍ 0.05
ation in the mammary glands of WT
vs. proestrous stage.
and Aromhum mouse lines. The numbers of Ki67-positive nuclei in the mammary epithelium of Aromhum mouse
and by the development of aberrant lobular structures.
However, mammary gland hyperplasia was reduced evi- lines were significantly higher than those in WT mice at 24
denced by decreased ductal side branching in F1772 wk of age (Fig. 6, A and C). Specifically, the percentage of
mice as compared with F1771 mice. Mammary glands Ki67-positive nuclei was 4.8-fold and 2.8-fold higher in
in Aromhum mice (F1772 and F1771 lines) showed a the mammary epithelium of F1771 and F1772 mice, remarked increase in lobuloalveolar hyperplasia and exhib- spectively, compared with WT mice (P ⬍ 0.05 for both).
ited extensive lipid droplets at 24 wk compared with WT We performed Ki67 immunohistochemistry in postmenomice (Fig. 5B). Keratinizing hyperplasia was also seen in pausal female mice (64 wk old) to preclude the variation
mammary glands of F1771 females (data not shown). The resulting from the estrous cycle. The percentage of Ki67percent of mice in each group showing hyperplasia was positive nuclei was similar between 24- and 64-wk-old
5-fold higher in F1771 mice and 3-fold higher in F1772 WT, F1772, and F1771 mice (Fig. 6, B and D).
mice compared with WT mice (Fig. 5C). We also investigated whether the lobuloalveoli in the Aromhum mice were Mammary aromatase expression is associated with
functional by measuring the expression levels of various phosphorylation of Stat5 in Aromhum mice
To better understand the activated signaling pathways
milk-specific mRNA transcripts and protein during pregnancy (34). ␤-casein mRNA levels were significantly in- associated with increased local estrogens production in
creased in F1771 mice compared with WT and F1772 breast tissue displaying hyperplasia and lipid droplets, we
mice; however, WDNM1 (also called extracellular pro- used immunoblotting to determine protein phosphorylateinase inhibitor or Expi) mRNA levels were similar be- tion in mammary glands of 24-wk-old females. Previous
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tween WT, F1772, and F1771 mice
(Fig. 5, D and E). To minimize differences on mammary gland histology and
milk protein levels resulting from the
estrous cycle, postmenopausal female
(64 wk old) mammary glands were analyzed. Lobuloalveolar hyperplasia in
Aromhum mice had a similar appearance at both 24 and 64 wk old (Fig. 5,
B and F). However, the percent of mice
exhibiting hyperplasia was higher in
WT and F1772 mice at 64 wk of age
compared with that at 24 wk of age and
similar in 1771 mice between 24 and 64
wk old (Fig. 5, C and G). Milk protein
␤-casein was significantly increased in
64-wk-old Aromhum as compared with
the WT littermates (Fig. 5H).
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studies showed that estrogens, via binding to cytoplasmic
or membrane receptors, rapidly activated intracellular signaling cascades such as Stat, ERK, or PI3K/Akt (35, 36).
As shown in Fig. 7, A and B, Western blot analysis showed
a significant increase in Stat5a phosphorylation in breast
tissue of F1771 mice compared with WT mice at the age
of 24 wk. Stat5 phosphorylation in postmenopausal females (64 wk) was measured to preclude possible cycle
stage-dependent variations. Similar differences were observed between 24-wk-old and 64-wk-old mice (Fig. 7, C
and D). Stat5a phosphorylation in F1772 mice was also
increased at 24 and 64 wk of age, but this difference was
not statistically significant. Phosphorylation of ERK or
Akt was not detectable in WT, F1772, or F1771 mice (data
not shown).

Discussion
We and others have shown that two distinct promoters
control aromatase expression in the ovary and brain of
female mice (12–14). However, additional alternative
promoters regulate aromatase expression in many extragonadal tissues (e.g. fat in breast, bone, and lung) in
women (11, 37). To mimic the human aromatase expression patterns and physiology related to local estrogen pro-

duction in various tissues, we generated Aromhum mouse
lines containing a single copy of the human aromatase
gene driven by its native tissue-specific promoters. The
aromatase expression pattern in Aromhum mammary
stroma and myoepithelia mimicked human aromatase expression in basal and stromal cells in human breast tissues
(38). The Aromhum mice produced excessive local estrogen
in breast tissue and displayed mammary lobuloalveolar
hyperplasia at 24 and 64 wk. This new mouse model is the
first of its kind. We predict that it will be a valuable tool
for developing tissue-specific aromatase inhibition
strategies.
The mammary gland undergoes most of its branching
during adolescence rather than during fetal development.
Hormone-dependent branching requires estrogen and
ER␣ expression in the breast (33). In this study, human
aromatase expression in mouse mammary stroma and
myoepithelia was associated with increased local estrogen
production and increased ductal elongation and outgrowth in the mammary gland during puberty compared
with WT littermates. However, WT and Aromhum mice
had similar levels of serum estrogens, suggesting an important role of local excessive mammary tissue estrogens
in stimulating linear ductal growth at puberty. These results are inconsistent with previous reports that described
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FIG. 5. Mammary lobuloalveolar hyperplasia in the Aromhum mouse. A, Whole-mount staining was performed on mammary glands from WT,
F1772, and F1771 mice at 24 wk of age (n ⫽ 5 mice per group). Bar, 1000 m. B, Hematoxylin and eosin (H&E) staining was performed on 24wk-old mammary gland tissue from WT, F1772, and F1771 mice (n ⫽ 4 or 5 mice per group). Bar, 50 m. C, Percentage of mice showing
mammary hyperplasia was determined based on H&E staining of mammary glands from 24-wk-old mice (n ⫽ 11 mice per group). mRNA
expression of milk proteins WDNM1 (D) and ␤-casein (E) in mammary glands of WT and Aromhum mice was measured by real-time RT-PCR and
normalized to GAPDH mRNA levels (n ⫽ 4 mice per group). *, P ⬍ 0.05 vs. WT mice. F, H&E staining was performed on 64-wk-old mammary
gland tissue from WT, F1772, and F1771 mice (n ⫽ 4 or 5 mice per group). Bar, 50 m. G, Percentage of mice showing mammary hyperplasia
from 64-wk-old mice (n ⫽ 5 mice per group). H, Milk protein ␤-casein was measured by Western blotting in WT and Aromhum mice at 64 wk of
age (n ⫽ 3– 4 mice per group).

2710

Zhao et al.

Aromatase Expression and Mammary Hyperplasia

Endocrinology, June 2012, 153(6):2701–2713

a role of systemic estrogen rather than local estrogen in
controlling mammary side branching (39).
Aromatase converts the androgens testosterone and androstenedione into E2 and E1, respectively. As expected,
humanized aromatase expression decreased systemic testosterone levels in the Aromhum mice, which was most
likely caused by suppression of LH by the additional local
production of estrogen driven by human aromatase expressed in the brain. Peripheral human aromatase expression probably does not account for the decreased testosterone in F1771 females because peripheral conversion of
testosterone to E2 is estimated to be approximately 1%
(11). A previous study showed that estrogens induced PR
expression and increased pituitary prolactin concentration (39, 40). However, in the present study, additional
estrogen production from the human aromatase gene did
not change circulating levels of prolactin, progesterone or
FSH nor did this effect on mRNA levels of PR or ER␣ in
the mammary gland. These results suggest that elevated

tissue estrogen production exerts selective effects on certain endocrine systems.
The Aromhum mice, containing a single copy of the entire human aromatase gene, mimicked human aromatase
expression pattern in mice and thus human physiology
with respect to estrogen production (41). This Aromhum
mouse model is unique and offers new opportunities for
studying estrogen-related physiology for the following
reasons. Because the Aromhum mice were generated via
autosomal insertion of a single copy of the entire human
aromatase gene, it produces physiological amounts of estrogen in relevant mouse tissues. Second, the tissue distribution pattern of human aromatase expression in Aromhum
females is nearly identical with that observed in
women. Third, physiologically relevant native promoters
control the human aromatase gene in a tissue-selective
fashion. Fourth, the physiological genetic mechanisms
such as binding of transcriptional activator or silencer
complexes to the native chromatin leading to alternative
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FIG. 6. Cell proliferation evaluated by Ki67 staining is higher in mammary epithelia of Aromhum mice compared with WT littermates. Ki67-positive
nuclei were detected at 24 wk (A) and 64 wk (B) of WT, F1772, and F1771 mice by immunostaining using an antibody against Ki67 (arrows). Bar,
50 m. A total of 2000 nuclei were counted in sections obtained from mice at 24 wk (C) and 64 wk of age (D) to calculate the percent of Ki67positive nuclei in WT and Aromhum mice (n ⫽ 3– 4 in each group). *, P ⬍ 0.05 vs. WT.
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was significantly increased in breast tissue of F1771 mice compared with WT
mice. However, not every mouse
showed the increased of Stat5 phosphorylation. This may be due to expected variations in gene expression
and signal transduction in transgenic
mice, which are frequently encountered. These data suggested that local
increased E2 could activate Stat5 and
that this could be a mechanism for
mammary hyperplasia and lipid droplet accumulation.
FIG. 7. Stat5 phosphorylation is increased in mammary gland of Aromhum mice.
The side effects observed during
Representative Western blot analysis in 24-wk-old (A) and 64-wk-old (C) and quantification of
treatment with the aromatase inhibiphosphorylated Stat5 in 24-wk-old (B) and 64-wk-old (D) mammary gland of WT and
Aromhum mice are shown. Mammary gland protein extracts from WT and Aromhum mice (25
tors are the result of global inhibition of
g proteins per sample) were subjected to immunoblot analysis using an antibody against
the aromatase activity in all tissues (18,
phosphorylated Stat5, Stat5a, and ␤-actin, as described in Materials and Methods (n ⫽ 3– 6
45, 46). Thus, the ideal therapeutic apmice in each group). *, P ⬍ 0.05 vs. WT.
proach to treatment of estrogen-reactivation of promoters, alternative splicing of an untrans- sponsive breast cancers would be the tissue-specific blocklated first exon to a common splice junction, and the rest age of estrogen production in the breast only. The
of the splicing events leading mRNA transcription and its development of tissue-selective aromatase inhibitors is
polyadenylation, all operate in a seemingly identical fash- plausible because of the tissue-specific regulation of aroion to that observed in the human body. Finally, the cel- matase expression (47, 48). Inhibition of promoter II/I.3lular distribution of the aromatase expression in the mam- mediated transcription might provide a breast-specific
mary tissue of mice matched our previously published therapy (20, 49); therefore, factors regulating transcripobservation in women (42).
tion from these promoters are currently being studied. BeThe insertion of a single copy of the human aromatase cause aromatase expression in the Aromhum model closely
gene into female mice gave rise to a remarkably increased resembles that in humans, the model may be useful for
frequency of lobuloalveolar hyperplasia in the mammary identifying signaling pathway inhibitors that can block
tissue, which was accompanied by increased mammary aromatase expression arising from promoters II and I.3
epithelial proliferation at 24 wk of age. Although these but permit the activation of promoters I.f, I.4, and I.6. This
findings may be associated with an increased risk of ma- would lead to the inhibition of all estrogen synthesis in the
lignancy in the long term, the incidence of mammary can- ovary and the majority of estrogen synthesis in the mamcer in these mice is currently unknown. It may be necessary mary gland but permit local estrogen production in the
to facilitate carcinogenesis chemically or by crossing these brain, bone, and at low levels in fat. This approach would
mice with a mildly tumorigenic genetic strain to assess the be sufficient to inhibit mammary hyperplasia and carcirole of the human aromatase gene in mammary carcino- nogenesis while maintaining the beneficial effects of esgenesis. This will be an active area of research in our trogen in other tissues. Such an approach may lead to
laboratory.
viable treatment options with fewer side effects compared
Prolactin plays a primary role in the physiological prowith the currently available aromatase inhibitor that
cess of mammary gland secretion through the activation of
causes whole-body estrogen deprivation. Our in vivo
various signaling cascades including Janus kinase-2/Stat5,
Aromhum model would be ideal for screening candidate
ERK, and PI3K/Akt (43). Stat5 was first found to be inselective aromatase inhibitors.
volved in the prolactin-induced ␤-casein gene expression
in mammary glands (44). Here we observed lipid droplet
accumulation in the mammary glands of Aromhum mice.
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